Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV 16/18 E6/E7 DNA vaccine pBI-11

A therapeutic codon-optimized DNA vaccine encoding for the E6 and E7 proteins of human papillomavirus (HPV) subtypes 16 and 18, with potential immunostimulating and antineoplastic activities. Upon administration, the HPV 16/18 E6/E7 DNA vaccine pBI-11 expresses the HPV 16/18 E6/E7 fusion protein which may elicit a specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HPV 16/18 E6 and E7 oncoproteins, resulting in tumor cell lysis. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis. Codon optimization of the HPV16/18 E6/E7 genes in pBI-11 improves fusion protein expression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DNA vaccine pBI-11
E6/E7 DNA vaccine pBI-11
Code name:pBI 11
pBI-11
pBI11
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search